Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

References

• DiehlLFKarnellLHMenckHRThe American College of Surgeons Commission on Cancer and the American Cancer Society. The national cancer data base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemiaCancer199986122684269210594864
   PubMed Web of Science ®Google Scholar
• NabhanCAschebrook-KilfoyBChiuBCThe impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern eraLeuk Lymphoma2014 Epub 2014 Apr 3
   Web of Science ®Google Scholar
• HallekMChesonBDCatovskyDInternational Workshop on Chronic Lymphocytic LeukemiaGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelinesBlood2008111125446545618216293
   PubMed Web of Science ®Google Scholar
• DoresGMAndersonWFCurtisREChronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiologyBr J Haematol2007139580981917941952
   PubMed Web of Science ®Google Scholar
• PanovskaADoubekMBrychtovaYMayerJChronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL)Clin Lymphoma Myeloma Leuk201010429730020709668
   PubMed Web of Science ®Google Scholar
• RaiKRSawitskyACronkiteEPChananaADLevyRNPasternackBSClinical staging of chronic lymphocytic leukemiaBlood19754622192341139039
   PubMed Web of Science ®Google Scholar
• HallekMFischerKFingerle-RowsonGInternational Group of Investigators, German Chronic Lymphocytic Leukaemia Study GroupAddition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialLancet201037697471164117420888994
   PubMed Web of Science ®Google Scholar
• RobakTDmoszynskaASolal-CélignyPRituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemiaJ Clin Oncol201028101756176520194844
   PubMed Web of Science ®Google Scholar
• SmolejLThe role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemiaExpert Opin Investig Drugs201221710091017
   PubMed Web of Science ®Google Scholar
• FischerKCramerPBuschRBendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study groupJ Clin Oncol201129263559356621844497
   PubMed Web of Science ®Google Scholar
• FischerKCramerPBuschRBendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study groupJ Clin Oncol201230263209321622869884
   PubMed Web of Science ®Google Scholar
• KeatingMJFlinnIJainVTherapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood200299103554356111986207
   PubMed Web of Science ®Google Scholar
• WierdaWGKippsTJMayerJHx-CD20-406 Study InvestigatorsOfatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemiaJ Clin Oncol201028101749175520194866
   PubMed Web of Science ®Google Scholar
• HillmenPRobakTJanssensAOfatumumab – chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement-1 (OMB 110911)Blood2013122528
   Web of Science ®Google Scholar
• BrownJRKimHTArmandPLong-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcomeLeukemia201327236236922955330
   PubMed Web of Science ®Google Scholar
• ByrdJCFurmanRRCoutreSETargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaN Engl J Med20133691324223782158
   PubMed Web of Science ®Google Scholar
• ByrdJCBrownJRO’BrienSRESONATE InvestigatorsIbrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaN Engl J Med2014371321322324881631
   PubMed Web of Science ®Google Scholar
• BrownJRByrdJCCoutreSEIdelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemiaBlood2014123223390339724615777
   PubMed Web of Science ®Google Scholar
• FurmanRRSharmanJPCoutreSEIdelalisib and rituximab in relapsed chronic lymphocytic leukemiaN Engl J Med201437011997100724450857
   PubMed Web of Science ®Google Scholar
• VoglerMDinsdaleDDyerMJCohenGMABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not plateletsBr J Haematol2013163113914223826785
   PubMed Web of Science ®Google Scholar
• KaterAPToninoSHEgleARamsayAGHow does lenalidomide target the chronic lymphocytic leukemia microenvironment? Blood2014124142184218925161268
   PubMed Web of Science ®Google Scholar
• EvansEKTesterRAslanianSInhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humansJ Pharmacol Exp Ther2013346221922823709115
   PubMed Web of Science ®Google Scholar
• AkinleyeAChenYMukhiNSongYLiuDIbrutinib and novel BTK inhibitors in clinical developmentJ Hematol Oncol201365923958373
   PubMed Web of Science ®Google Scholar
• DongSGuinnDDubovskyJAIPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cellsBlood2014 Epub 2014 Sep 25
   Web of Science ®Google Scholar
• PorterDLLevineBLKalosMBaggAJuneCHChimeric antigen receptor-modified T cells in chronic lymphoid leukemiaN Engl J Med2011365872573321830940
   PubMed Web of Science ®Google Scholar
• Obinutuzumab (Gazyvaro)Summary of product characteristics2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002799/WC500171596.pdfAccessed October 17, 2014
   Google Scholar
• PoppemaSVisserLPreparation and application of monoclonal antibodies: B cell panel and parafin tissue reactive panelBiotest Bull19873131139
   Google Scholar
• MössnerEBrünkerPMoserSIncreasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicityBlood2010115224393440220194898
   PubMed Web of Science ®Google Scholar
• BeersSAChanCHFrenchRRCraggMSGlennieMJCD20 as a target for therapeutic type I and II monoclonal antibodiesSemin Hematol201047210711420350657
   PubMed Web of Science ®Google Scholar
• HerterSHertingFMundiglOPreclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft modelsMol Cancer Ther201312102031204223873847
   PubMed Web of Science ®Google Scholar
• HertingFFriessTBaderSEnhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphomaLeuk Lymphoma20145592151516024304419
   PubMed Web of Science ®Google Scholar
• RafiqSButcharJPCheneyCComparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage propertiesJ Immunol201319062702271123418626
   PubMed Web of Science ®Google Scholar
• KernDJJamesBRBlackwellSGassnerCKleinCWeinerGJGA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is presentLeuk Lymphoma201354112500250523452151
   PubMed Web of Science ®Google Scholar
• NiederfellnerGLammensAMundiglOEpitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodiesBlood2011118235836721444918
   PubMed Web of Science ®Google Scholar
• HoneychurchJAlduaijWAzizyanMAntibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathwayBlood2012119153523353322354003
   PubMed Web of Science ®Google Scholar
• AlduaijWIvanovAHoneychurchJNovel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignanciesBlood2011117174519452921378274
   PubMed Web of Science ®Google Scholar
• DalleSReslanLBesseyre de HortsTPreclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101Mol Cancer Ther201110117818521220500
   PubMed Web of Science ®Google Scholar
• BolognaLGottiEManganiniMMechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumabJ Immunol201118663762376921296976
   PubMed Web of Science ®Google Scholar
• CartronGde GuibertSDilhuydyMSObinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN studyBlood2014124142196220225143487
   PubMed Web of Science ®Google Scholar
• Meneses-LorenteGCarlileDBirkettJWengerMKCartronGMorschhauserFPharmacokinetics of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease (phase I/II study BO20999)Blood20101161833
   Web of Science ®Google Scholar
• SehnLHAssoulineSEStewartDAA phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignanciesBlood2012119225118512522438256
   PubMed Web of Science ®Google Scholar
• GoedeVFischerKBuschRObinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsN Engl J Med2014370121101111024401022
   PubMed Web of Science ®Google Scholar
• GoedeVFischerKBuschRChemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-inLeukemia20132751172117422936013
   PubMed Web of Science ®Google Scholar
• US National Institutes of Health2014 Available from: http://clinicaltrials.gov/ct2/results?term=obinutuzumab+AND+CLL&recr=OpenAccessed October 22, 2014
   Google Scholar